Carfilzomib is a novel, highly selective tetrapeptide epoxyketone proteasome inhibitor for use in patients with multiple myeloma who have received at least two prior therapies and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Baloxavir marboxil, marketed as Xofluza, is a first-in-class, one-dose oral agent first approved by the FDA in 2018 for the treatment of acute, uncomplicated influenza in individuals 12 years and older, who have been symptomatic for less than 24 hours.
Copyright © 2013-2019 Hunan HuaTeng Pharmaceutical Co., Ltd. All right reserved Tel: +86-0731-82251112 ex 814 / 815, +1 857-928-2050 E-mail: email@example.com
Address: Lugu Business Plaza E1, Yuelu District, Changsha City, Hunan Province, P.R. China. ZIP Code: 410006